NCT04462471 2025-09-08
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
Memorial Sloan Kettering Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
National Cancer Institute (NCI)